ArticleMolecular brain2025
BDNF genotype associated with changes in cortical thickness, severity of symptoms, and cognitive impairments in mild traumatic brain injury.
Article in Molecular brain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveBrain-derived neurotrophic factor (BDNF) is a critical blood protein for brain function; however, its genotypic influence on clinical outcomes and brain structure following mild traumatic brain injury (mTBI) remains unclear. This study investigated the relationship between BDNF polymorphisms and cognitive impairment, symptom severity, and cortical structural injury in mTBI patients. MATERIALS AND
methodsSixty-one mTBI patients underwent neuropsychological assessments and MRI scans within one week post-injury, with 46 patients followed up at one month. Fifty-two healthy controls were included for comparison. Patients with mTBI exhibited clinical symptoms, cognitive impairment, and alterations in cortical thickness during in the acute phase.
resultsBDNF Met gene carriers (n = 41) and Val gene carriers (n = 20) demonstrated different cognitive performance in the acute phase and exhibited distinct recovery trajectories. Val carriers showed significantly better cognitive flexibility compared to Met carriers (p = 0.028) during the acute phase and greater improvement in clinical symptoms at one month (p = 0.035). Follow-up MRI scans revealed more extensive and statistically significant alterations in cortical thickness in Met carriers than in Val carriers (p < 0.01), particularly in regions associated with cognitive and emotional regulation.
conclusionThese findings suggest that BDNF polymorphisms in mTBI patients are associated with brain structural changes and may serve as valuable biomarkers for identifying individuals at risk for long-term clinical symptoms and cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.